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Background: Nifekalant is a unique class III anti-arrhythmic agent with a strong eﬀect on
prolonging the myocardial refractoriness, but its clinical eﬀect is still unclear. In this study,
we evaluated the eﬀect of nifekalant on life-threatening ventricular arrhythmias and compared
the clinical background between the eﬀective and non-eﬀective patients in order to clarify the
clinical factors which may have an inﬂuence on the eﬃcacy of nifekalant.
Methods: The study population consisted of 47 consecutive patients who underwent
nifekalant administration for life-threatening ventricular arrhythmias (VT/VF). Their clinical
characteristics and ECG parameters were retrospectively compared between patients with and
without an eﬀective result with the nifekalant administration.
Results: Nifekalant was eﬀective for refractory VT/VF in 26/47 patients. There was no
signiﬁcant diﬀerence in the age, gender or left ventricular ejection fraction, but the incidence
of ischemic heart disease was higher in the eﬀective group (17/26) than non-eﬀective group
(9/21, p ¼ 0:004). The incidence of in-hospital events was higher in the eﬀective group than
non-eﬀective group (20/26 vs 10/21, p ¼ 0:037). A signiﬁcant prolongation in the QTc
interval was observed in all patients and the degree of QTc prolongation was greater in the
eﬀective group than in the non-eﬀective group (0:46 0:04 vs 0:43 0:02 sec1=2,
p ¼ 0:026).
Conclusion: Nifekalant was eﬀective in 55% of the patients for refractory VT/VF. It was
considered that nifekalant was more eﬀective for patients with ischemic heart disease, during
the perioperative period or in those experiencing in-hospital events. The prolongation of the
QTc interval might also be useful as an index for the eﬃcacy of nifekelant administration.
(J Arrhythmia 2008; 24: 141–148)
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Introduction
The incidence of sudden cardiac death (SCD) has
been reported to be more than 300,000 annually in
the United States, and it commonly appears as a
result of life-threatening ventricular arrhythmias due
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to acute coronary events.1,2) Although the prevalence
of ischemic heart disease might diﬀer in Japan, the
importance of appropriate therapy for life-threat-
ening ventricular arrhythmias is similar in order to
save patients from SCD in those with serious
ventricular arrhythmias. Although an intravenous
injection of amiodarone has been recommended as
the ﬁrst-line therapy for refractory ventricular ar-
rhythmias in the American and European therapeutic
guidelines, it was not available in Japan until the
middle of 2007.3) Prior to that time, we had
considerable experience administering nifekalant,
a pure Ikr channel blocker, as the only class III
antiarrhythmic agent available for intravenous in-
jections in Japan for the management of refractory
ventricular arrhythmias.4–6) Although we sometimes
experienced patients with life-threatening arrhyth-
mias in whom nifekalant exhibits dramatic eﬃcacy,
the incidence and patient characteristics of nifekalant
as a treatment modality remains unclear. In the
present study, we evaluated the eﬃcacy of nifekelant
on refractory ventricular arrhythmias and also
evaluated the clinical characteristics of the patients
with eﬀective or non-eﬀective results with nifekalant
usage in order to clarify the clinical usefulness of
nifekalant in managing refractory arrhythmias.
Methods
The study population consisted of 47 consecutive
patients who underwent nifekalant administration for
the treatment of lidocaine refractory life-threatening
ventricular arrhythmias, i.e., ventricular tachycardia
or ﬁbrillation (VT/VF), in Kitasato University
Hospital from November 1999 to February 2007.
The mean age was 63 6 years, and 13 were female
and 34 male. They were retrospectively analyzed
for the purpose of this study. The underlying heart
disease was diagnosed as ischemic heart disease in
26, idiopathic dilated or hypertrophic cardiomyop-
athy in 16, and valvular heart disease in 5 patients.
The diagnoses were made from the ﬁndings in the
preceding examinations including the echocardio-
gram (32/47) and/or cardiac catheterization (24/
47), but in the remaining patients (15/47), the
diagnoses were made from the ﬁndings after or
during the treatment for VT/VF.
The lidocaine refractory VT/VF was deﬁned as
1) VT/VF which could not be interrupted by an
intravenous lidocaine injection of 50mg even with
direct current deﬁbrillation, or 2) recurrent VT/VF
which could not be prevented by an intravenous
lidocaine injection of 50mg even after a successful
cardioversion. Nifekalant was used for VT/VF
interruption or deﬁbrillation enhancement4) for
continuous VT/VF, and it was used for VT/VF
prevention or maintenance of sinus rhythm for
recurrent VT/VF.4) Nifekalant was administered at
an initial dose of 0.1–0.4mg/kg over 5 minutes,
and it was followed by a continuous infusion at a
dose of 0.4mg/kg/h when necessary for maintaining
sinus rhythm in the patients with eﬀective results.4,7)
The eﬃcacy of nifekalant was considered as eﬀec-
tive when one of the following ﬁndings was
obtained after the initial infusion of nifekalant,
i.e., 1) interruption of lidocaine refractory VT/VF,
2) change in the DC cardioversion results from being
non-eﬀective to eﬀective for lidocaine refractory
VT/VF, or 3) prevention of any repetitive lidocaine
refractory VT/VF.4) During and after the infusion of
nifekalant, the QT interval was continuously moni-
tored and the dose of the nifekalant was decreased
when the QTc interval was prolonged by more than
0.60 sec1=2.4,8)
In these patients, the clinical background includ-
ing the age, gender, underlying heart disease, left
ventricular ejection fraction (LVEF), type of targeted
arrhythmia, purpose of nifekalant usage, conditions
at the onset of the arrhythmic events and relationship
to the operative procedure were examined. In
patients with in-hospital events, the time interval
from the event onset to the start of nifekalant therapy
was evaluated. We obtained the ECG parameters and
LVEF data from the echocardiogram during sinus
rhythm, but in cases in which no stable sinus rhythm
could be achieved (n ¼ 11), those parameters were
excluded from the evaluation in this study. The
levels of the serum creatinine, potassium, and brain
natriuretic peptide were examined at the time of the
VT/VF event. The patients were divided into two
groups in accordance with the eﬀect of the initial
injection of nifekalant on the refractory VT/VF, and
the parameters described above were compared
between the two groups. Similar comparison of the
parameter was also performed in subgroup of diﬀer-
ent purpose of nifekalant therapy, i.e., VT/VF
interruption and VT/VF prevention. All evaluations
were performed after obtaining informed consent
from patient or patient’s family and with the
approval of the Committee of Clinical Ethics at
Kitasato University Hospital.
Statistics
The data were expressed as the mean SD. A one
way ANOVA was used for the continuous values
and the Mann-Whitney U test was used for compar-
isons between groups of discrete variables, and P <
0:05 was considered as signiﬁcant. All mathematical
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computations and statistical procedures were per-
formed using the JMP software (SAS Institute Inc.).
Results
Nifekalant was used for the purpose of VT/VF
interruption in 19/47 and for VT/VF prevention in
28/47 patients. In 19 patients with therapy for VT/
VF interruption, VT/VF interruption during nifeka-
lant infusion was observed in 5, and deﬁbrillation
enhancing eﬀect4) was observed in the other 5
patients. In 28 patients with therapy for VT/VF
prevention, sinus rhythm was maintained in 16
patients. In total, nifekalant was eﬀective in 26/47
patients who were classiﬁed as the nifekalant
eﬀective group, and the remaining 21 patients were
deﬁned as the non-eﬀective group. In 16/21 patients
with non-eﬀective results, a stable sinus rhythm
could not be achieved and percutaneous cardiopul-
monary support (PCPS) was later applied. Table 1
exhibits the clinical characteristics of the two groups.
There were no signiﬁcant diﬀerences in the age,
gender, targeted arrhythmia, LVEF or the level of
serum creatinine, potassium or BNP between the two
groups. In regard to the underlying heart disease, the
incidence of acute ischemic heart disease was higher
in the eﬀective group and that of cardiomyopathy
was higher in the non-eﬀective group (p ¼ 0:005).
Of the 47 patients, the place of event onset was
outside the hospital in 17 and inside the hospital in
30 patients. The incidence of in-hospital events was
higher in the eﬀective group (20/26) than in the non-
eﬀective group (10/21, p ¼ 0:037). There were 25/
47 patients with a perioperative (cardiac surgery and
coronary angioplasty) onset of the event, including
during percutaneous coronary intervention. The
incidence of onset during a perioperative event was
also higher in the eﬀective group (18/26) than in the
non-eﬀective group (7/21, p ¼ 0:014). In patients
with an in-hospital event, the time from event onset
to nifekalant therapy tended to be shorter in the
eﬀective group than in the non-eﬀective group, but
the diﬀerence was not signiﬁcant. The survival rate
of patients was higher in the eﬀective group, as
none of the non-eﬀective group patients survived
(p ¼ 0:0003).
Tables 2 and 3 compare the characteristics of
patients in the subgroups according to the purpose
of the nifekalant therapy. Although data showed a
trend similar to that for all patients, a signiﬁcant
Table 1 Clinical characteristics of all patients
Total Nifekalant
effective
Nifekalant
non-effective p value
Number (n) 47 26 21
Age (years) 63 6 64 5 61 6 0.056
Gender (F:M) 13:34 8:18 5:16 0.595
Basic heart disease
(AIHD/OIHD/CM/others) 7/19/16/5 6/11/4/5 1/8/12/0 0.005
Perioeprative state (n) 25/47 18/26 7/21 0.014
In-hospital event (n) 30/47 20/26 10/21 0.037
Time to nifekalant therapy (min)y 26 8 23 8 29 10 0.0891
Discharge alive (n) 12/47 12/26 0/21 0.0003
Targetted arrhythmia
(VF/poly VT/VT) 19/23/5 7/16/3 12/7/2 0.102
Purpose of Therapy
(interruption, prevention) 19/28 10/16 9/12 0.761
Initial dose of nifekalant (mg) 23:9 3:5 24:2 3:3 23:4 3:7 0.529
LVEF (%) 36 5 37 5 35 4 0.095
Serum creatinine (mg/dl) 1:5 0:5 1:4 0:5 1:6 0:5 0.112
Serum potassium (mEq/L) 4:3 0:4 4:3 0:3 4:4 0:4 0.332
BNP (ng/dl) 826 494 932 498 782 488 0.307
A&OIHD: acute and old ischemic heart disease, CM: cardiomyopathy,
VF: ventricular ﬁbrillation, poly VT: polymorphic VT, VT: monomorphic VT
LVEF: left ventricular ejection fraction, BNP: brain natriuretic peptide
yCalculated in 20 eﬀective and 10 non-eﬀective patients with in-hospital event.
 indicates statistical signiﬁcance.
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diﬀerence was observed only in patient survival in
patients with nifekalant therapy for VT/VF inter-
ruption (Table 2). In patients with nifekelant therapy
for VT/VF prevention, on the other hand, the
incidence of cardiomyopathy was higher in the
non-eﬀective group than the eﬀective group
Table 2 Characteristics of the patients with nifekalant therapy for VT/VF interruption
Total Nifekalant
effective
Nifekalant
non-effective p value
Number (n) 19 10 9
Age (years) 62 6 64 6 60 6 0.177
Gender (F:M) 8:11 5:5 3:6 0.463
Basic heart disease
(AIHD/OIHD/CM/others) 3/8/7/1 3/2/4/1 0/6/3/0 0.107
Perioeprative state (n) 10/19 7/10 3/9 0.111
In-hospital event (n) 11/19 7/10 4/9 0.259
Time to nifekalant therapy (min)y 24 9 25 10 24 8 0.887
Discharge alive (n) 6/19 6/10 0/9 0.005
Targetted arrhythmia
(VF/poly VT/VT) 8/10/1 3/6/1 5/4/0 0.102
Initial dose of nifekalant (mg) 22:9 3:4 23:6 3:6 22:0 3:2 0.312
LVEF (%) 36 5 37 4 34 5 0.183
Serum creatinine (mg/dl) 1:5 0:6 1:4 0:6 1:7 0:4 0.148
Serum potassium (mEq/L) 4:2 0:4 4:3 0:4 4:2 0:3 0.517
BNP (ng/dl) 890 512 835 446 950 597 0.601
A&OIHD: acute and old ischemic heart disease, CM: cardiomyopathy,
VF: ventricular ﬁbrillation, poly VT: polymorphic VT, VT: monomorphic VT
LVEF: left ventricular ejection fraction, BNP: brain natriuretic peptide
yCalculated in 7 eﬀective and 4 non-eﬀective patients with in-hospital event.
indicates statistical signiﬁcance.
Table 3 Characteristics of the patients with nifekalant therapy for VT/VF prevention
Total Nifekalant
effective
Nifekalant
non-effective p value
Number (n) 28 16 12
Age (years) 63 6 65 5 61 7 0.158
Gender (F:M) 5:23 3:13 2:10 0.887
Basic heart disease
(AIHD/OIHD/CM/others) 4/12/8/4 3/7/2/4 1/5/6/0 0.038
Perioeprative state (n) 15/28 11/16 4/12 0.063
In-hospital event (n) 19/28 13/16 6/12 0.078
Time to nifekalant therapy (min)y 27 9 24 7 33 11 0.024
Discharge alive (n) 6/28 6/16 0/12 0.017
Targetted arrhythmia
(VF/poly VT/VT) 11/13/4 4/10/2 7/3/2 0.129
Initial dose of nifekalant (mg) 24:6 3:3 24:6 3:1 24:7 3:7 0.889
LVEF (%) 37 5 38 4 34 4 0.108
Serum creatinine (mg/dl) 1:5 0:5 1:4 0:4 1:7 0:6 0.139
Serum potassium (mEq/L) 4:4 0:4 4:3 0:4 4:5 0:5 0.103
BNP (ng/dl) 849 489 992 532 798 365 0.112
A&OIHD: acute and old ischemic heart disease, CM: cardiomyopathy,
VF: ventricular ﬁbrillation, poly VT: polymorphic VT, VT: monomorphic VT
LVEF: left ventricular ejection fraction, BNP: brain natriuretic peptide
yCalculated in 13 eﬀective and 6 non-eﬀective patients with in-hospital event.
indicates statistical signiﬁcance.
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(p ¼ 0:038) and the time from event onset to
nifekelant therapy was signiﬁcantly shorter in the
eﬀective group than the non-eﬀective group
(p ¼ 0:024), in addition to the diﬀerence in patient
survival (p ¼ 0:017).
Figure exhibits the changes in the electrocardio-
graphic parameters caused by the initial adminis-
tration of nifekalant. There was no diﬀerence
between the data before and after the nifekalant
administration in terms of the heart rate or QRS
width. The QTc interval was signiﬁcantly pro-
longed by nifekalant administration in both groups,
and the degree of the QTc prolongation was greater
in the eﬀective group than in the non-eﬀective
group.
Table 4 exhibits the comparison of the data of the
Heart rate QRS width
QTc
130
(bpm)
89±22 87±1495±13 91±13
(sec)
0.13
±0.02
0.12
±0.02
0.12
±0.02
0.13
±0.02
(sec1/2)
0.41 
±0.02
0.42
±0.02
0.46
±0.04
0.43 
±0.02
NS NS NS NS
p=0.046p=0.003
p=0.026
100
110
120
90
0.16
0.18
0.48
0.50
0.46
0.52
50
70
60
80
0.12
0.14
0.40
0.42
0.38
0.44
Effective Non-effective
pre post pre post
40
Effective
(n=24)
Non-effective
(n=12)
pre post pre post
0.10
Effective
(n=24)
Non-effective
(n=12)
pre post pre post
0.36
(n=24) (n=12)
Therapy for VT/VF interruption
Therapy for VT/VF prevention
Figure Changes in the ECG parameters with nifekalant
administration.
This ﬁgure exhibits the changes in the electrocardiographic
parameters caused by the initial administration of nifekalant.
Each line indicates the individual data of each patient. Dotted line
indicates the data of patients with nifekelant therapy for VT/VF
interruption and solid line indicates the data of patients with
therapy for VT/VF prevention. There was no diﬀerence between
the data before and after the nifekalant administration in terms of
the heart rate or QRS width. The QTc interval was signiﬁcantly
prolonged in both groups, and the degree of the prolongation was
greater in the eﬀective group than in the non-eﬀective group.
QTc: corrected QT interval
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patients with in-hospital and out-of-hospital events.
Because all perioperative events were observed as
in-hospital events, the incidence of perioperative
events was signiﬁcantly diﬀerent between the pa-
tients who had in-hospital versus those who had out-
of-hospital events. The population of underlying
heart disease was diﬀerent between the in-hospital
and out-of-hospital event patients, and the incidence
of acute and old ischemic heart disease was higher in
in-hospital event patients and that of cardiomyop-
athy was higher in out-of-hospital event patients
(p ¼ 0:012). There was no diﬀerence in patient
survival between the two groups.
Adverse eﬀects such as appearance of torsades de
pointes, bradycarida (<50 bpm), or abnormal QT
prolongation (QTc > 0:6 sec1=2) was not observed in
this study after the initial administration of nifeka-
lant.4,8) Later appearance of abnormal QTc prolon-
gation was observed in 2/22 patients with continu-
ous infusion of nifekalant and the dose of nifekelant
was reduced in such patients.
Discussion
Clinical effects of nifekalant and patient charac-
teristics
In this study, the eﬀect of nifekelant on lidocaine-
refractory VT/VF was evaluated in 47 consecutive
patients. Although the population included clinically
severe patients who underwent circulatory pulmo-
nary resuscitation procedures, nifekalant was eﬀec-
tive in suppressing VT/VF in 26/47 patients which
closely matched the VT/VF results of earlier
studies4,7) and was much better than that reported
for CPA patients.9) Because the population in this
study was selected as ‘‘lidocaine-refractory’’ VT/VF,
the arrhythmogenic substrate might be diﬀerent from
that of the total population. The main eﬀects of
lidocaine are conduction block due to sodium
channel blocking, and the suppression of triggered
activity due to the shortening of action potential
duration. Therefore the selection of the patients with
‘‘lidocaine-refractory’’ VT/VF might have resulted
in the selection of VT/VF with more chaotic and
functional reentrant circuits which is not strongly
dependent on the presence of triggered activity.
Nifekalant is a pure Ikr channel blocker and it
exhibits a prolongation of the myocardial refractori-
ness and enlargement of the central line of block in
spiral or leading circle reentry.10,11) It also leads to
exaggeration and irregular meandering of spiral
waves and may result in the interruption of tachy-
cardia by the collision of the central core to
anatomical obstacles.11–13) This eﬀect of nifekalant
Table 4 Copmarison of patients with in- and outside-hospital events
In-hospital
events
Outside-hospital
events p value
Number (n) 30 17
Age (years) 63 6 62 6 0.591
Gender (F:M) 7:23 6:11 0.378
Basic heart disease
(AIHD/OIHD/CM/others) 6/16/6/2 1/3/10/3 0.012
Perioeprative state (n) 25/30 0/17 <0:001
Discharge alive (n) 9/30 3/17 0.351
Targetted arrhythmia
(VF/poly VT/VT) 10/16/4 9/7/1 0.381
Efﬁcacy of nifekalant
for VT/VF interrruption (n) 7/11 3/8 0.257
for VT/VF prevention (n) 13/19 3/9 0.069
Initial dose of nifekalant (mg) 24.4  3.3 23.1  3.6 0.219
LVEF (%) 37 5 35 5 0.108
Serum creatinine (mg/dl) 1.5  0.6 1.5  0.5 0.959
Serum potassium (mEq/L) 4.3  0.4 4.5  0.4 0.521
BNP (ng/dl) 912 472 821 543 0.285
A&OIHD: acute and old ischemic heart disease, CM: cardiomyopathy,
VF: ventricular ﬁbrillation, poly VT: polymorphic VT, VT: monomorphic VT
LVEF: left ventricular ejection fraction, BNP: brain natriuretic peptide
indicates statistical signiﬁcance.
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might make it more eﬀective for the present
population than the total population.
In the present study, the incidence of in-hospital
events or perioperative events was higher in the
nifekalant eﬀective group than in the non-eﬀective
group. In a study in CPA patients, Yoshioka et al.9)
have suggested the inﬂuence of the diﬀerence
between in-hospital and out-of-hospital CPA in the
levels of acidosis, serum potassium, or preceding
use of epinephrine or lidocaine, but there was no
signiﬁcant diﬀerence in such factors in this study.
The precise mechanisms of those results were
unclear, but the time from the event onset to the
active treatment seemed to play at least one
important role. Because the perioerative patients
were usually under intensive monitoring, the interval
from the event onset to the time of the treatment
should have been the shortest. Although the data was
selected in patients with in-hospital events, the time
interval from the event onset to nifekelant admin-
istration tended to be shorter in the eﬀective group
than the non-eﬀective group and the diﬀerence was
signiﬁcant in patients with nifekalant therapy for
VT/VF prevention. Additionally, the incidence of
acute ischemic heart disease was higher in the
eﬀective group and cardiomyopathy was more
prevalent in the non-eﬀective group. It would be
partly explained by the correlation between the
underlying heart disease and the place of event onset
in the population of the present study (Table 4), but
nifekalant might be less eﬀective in cardiomyopathy
than in ischemic heart disease.14) The mechanism of
this diﬀerence is unclear but it might be explained by
the electrical or structural remodeling in chronic
heart failure which is characterized by the prolonga-
tion in action potential duration and decrease in cell-
to-cell connection.15) Because there might be multi-
ple small anatomical obstacles due to weak cell-to-
cell connections, small stable reentry may play a role
in such ventricle and therefore class III antiarrhyth-
mic agent might be less eﬀective. In contrast, the
shortening of action potential duration and trans-
mural dispersion are considered to play a role in
acute ischemia, and the eﬀect of nifekalant in
prolonging the action potential and decreasing trans-
mural dispersion would be more eﬀective in such
cases.16)
In the electrocardiographic parameters, the QTc
interval was signiﬁcantly prolonged by nifekelant
and the degree of the QTC prolongation was greater
in the eﬀective group than in the non-eﬀective group
(Figure). That result indicated that the QTc prolon-
gation caused by the nifekalant may vary in
individual patients even with the same amount of
the drug, and more eﬀective results would be
expected in patients with a larger QTc prolongation.
Because nifekalant is considered to interrupt the
tachycardia by prolonging the action potential
duration of the ventricular muscle, the strength
of the antiarrhythmic eﬀect of nifekalant could
be monitored by the degree of the QTc prolon-
gation.
Effect of nifekalant on patient survival
Reﬂecting the severe conditions of the patients,
the survival rate of the patients was considerably low
in our series (12/47). There were no survivors in the
nifekalant non-eﬀective group and all the survivors
were in the nifekalant eﬀective group. Interestingly,
the incidence of survivors in the nifekalant eﬀective
patients tended to be higher in the non-operative
patients (5/7) than in the perioperative patients
(7/18) although the diﬀerence was not signiﬁcant.
This probably indicates that the patients’ short-term
prognoses was strongly dependant on the success of
the initial treatment for life-threatening arrhythmias,
but the long-term prognoses would have been
determined by the underlying heart diseases them-
selves.
Limitations
This study evaluating the eﬀect of nifekalant on
lidocaine-refractory VT/VF had several limitations.
First, the study was designed retrospectively, there-
fore the basic therapies and backgrounds varied
among the patients. Second, the number of patients
was limited. Third, because the patients were
selected as a lidocaine refractory VT/VF popula-
tion, the characteristics of patients with lidocaine
eﬀective VT/VF are unclear. Finally, the time
points for the evaluation of the arrhythmias and
clinical parameters were limited, and thus the time
course of the changes in those parameters were
unclear.
Conclusions
Nifekalant was eﬀective in 24/47 (55%) of the
patients for lidocaine refractory VT/VF. It was
considered that nifekalant was more eﬀective for
patients with ischemic heart disease, during the
perioperative period or in those experiencing in-
hospital events, and less eﬀective for patients with
cardiomyopathy. The prolongation of the QTc
interval might also be useful as an index for the
eﬃcacy of nifekelant administration.
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